The Tom Baker Cancer Centre Clinical Trials Unit is dedicated to supporting the ongoing quest for more effective treatments for cancer patients through the conduct of cancer clinical trials. Its active clinical trials program meets the needs of patients to have access to the latest treatment innovations and contributes to the Tom Baker Cancer Centre’s standing as a centre of excellence in cancer care and research.

The Tom Baker Cancer Centre (TBCC) Clinical Trials Unit (CTU) is led by Dr. Gwyn Bebb (Medical Director) and Ms. Patricia Steele (CTU Manager), and consists of 50 staff members (research nurses, clinical research co-ordinators and research assistants). Funding for CTU core operations was made possible through a partnership between Alberta Cancer Foundation and CancerControl Alberta. 

The core operations staff includes the operational manager, an assistant unit manager, audit and regulatory co-ordinator, grant administrator, administrative assistant, two research assistants, as well as 13 research nurses and 23 clinical trial co-ordinators to support co-operative trial activities. Clinical trials services are available at the Tom Baker Cancer Centre and at the Holy Cross site.

TBCC oncologists work in close partnership with the CTU to offer 100-125 clinical trials available for patient enrollment.   Since operating as an organized unit, the CTU has put more than 6700 patients on clinical trials.  The CTU staff has an exemplary track record for conducting industry-sponsored, co-operative group and investigator-initiated clinical trials in all phases, including Phase I.

 

CTU Medical Director
Dr. Gwyn Bebb, BMBCh, PhD, FRCPC


Dr. Gwyn Bebb is currently practicing as a medical oncologist with a clinical focus in the treatment of lung malignancies. He is the medical leader of the Clinical Research Unit at the Tom Baker Cancer Centre and is principal investigator on a number of clinical trials. He is an active investigator in the Translational Research Laboratory with current research involving targeted therapy in vitro and in vivo of Mantle Cell Lymphoma (MCL) and non-small-cell lung cancer (NSCLC), EGFR (epidermal growth factor receptor) mutations in non-small-cell lung cancer and oncolytic virus in MCL and NSCLC.

As associate professor of medicine with the University of Calgary, Dr. Bebb has a keen interest in educating medical students, residents and other healthcare professionals.